PIQ 3.31% 87.5¢ proteomics international laboratories ltd

Ann: Sonic Healthcare USA signs licence for PromarkerD in the US, page-50

  1. 9,508 Posts.
    lightbulb Created with Sketch. 661
    Promarker D Promarker D, developed by Proteomics, is a predictive screening tool. While yet to be approved by the Therapeutic Goods Administration, it offers an insight into the growing ability to use blood checks as a preventive diagnostic. It claims the ability to predict the development of diabetic kidney disease up to four years in advance, allowing people the chance to act on medications and lifestyle changes earlier, diminishing the extent of kidney damage. Promarker D is conducted through a routine blood check which is sent to a laboratory for analysis, with results returned to the health professional.

    Above you find the part where Promarker D is mentioned in the article
 
watchlist Created with Sketch. Add PIQ (ASX) to my watchlist
(20min delay)
Last
87.5¢
Change
-0.030(3.31%)
Mkt cap ! $114.6M
Open High Low Value Volume
90.0¢ 92.5¢ 87.5¢ $228.5K 253.1K

Buyers (Bids)

No. Vol. Price($)
4 20150 87.0¢
 

Sellers (Offers)

Price($) Vol. No.
88.0¢ 3000 1
View Market Depth
Last trade - 15.55pm 09/09/2024 (20 minute delay) ?
PIQ (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.